Thymosinα1 stimulates cell proliferation by activating ERK1/2, JNK, and increasing cytokine secretion in human pancreatic cancer cells

Cancer Letters

Volumn 248, Issue 1, 2007, Pages 58-67

  Li, Min ^a   Feurino, Louis W ^a   Li, Fei ^a   Wang, Hao ^a   Zhai, Qihui ^b   Fisher, William E ^a   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Cell proliferation; Cytokine; Pancreatic cancer; Phosphorylation; Thymosin 1

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STRESS ACTIVATED PROTEIN KINASE; THYMOSIN ALPHA1; DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; THYMOSIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION; TH2 CELL; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-17; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH2 CELLS; THYMOSIN;

EID: 33847335620     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.05.019     Document Type: Article

References (50)

1. Sasaki H., Nonaka M., Fujii Y., Yamakawa Y., Fukai I., Kiriyama M., and Sasaki M. Expression of the prothymosin-a gene as a prognostic factor in lung cancer. Surg. Today 31 (2001) 936-938
2. Chen C., Li M., Yang H., Chai H., Fisher W., and Yao Q. Roles of thymosins in cancers and other organ systems. World J. Surg. 29 (2005) 264-270
3. Sarandeses C.S., Covelo G., Diaz-Jullien C., and Freire M. Prothymosin alpha is processed to thymosinα1 and thymosinα11 by a lysosomal asparaginyl endopeptidase. J. Biol. Chem. 278 (2003) 13286-13293
4. Sjogren M.H. Thymalfasin: an immune system enhancer for the treatment of liver disease. J. Gastroenterol. Hepatol. 19 (2004) S69-S72
5. Bianco N.R., and Montano M.M. Regulation of prothymosin alpha by estrogen receptor alpha: molecular mechanisms and relevance in estrogen-mediated breast cell growth. Oncogene 21 (2002) 5233-5244
6. Pineiro A., Cordero O.J., and Nogueira M. Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides 21 (2000) 1433-1446
7. Hugle T., and Cerny A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev. Med. Virol. 13 (2003) 361-371
8. Garaci E., Pica F., Rasi G., and Favalli C. Thymosinα1 in the treatment of cancer: from basic research to clinical application. Int. J. Immunopharmacol. 22 (2000) 1067-1076
9. Hadden J.W. Immunodeficiency and cancer: prospects for correction. Int. Immunopharmacol. 3 (2003) 1061-1071
10. Liaw Y.F. Thymalfasin (thymosin-α1) therapy in patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19 (2004) S73-S75
11. Rasi G., Pierimarchi P., Sinibaldi Vallebona P., Colella F., and Garaci E. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int. Immunopharmacol. 3 (2003) 1169-1176
12. Romani L., Bistoni F., Gaziano R., Bozza S., Montagnoli C., Perruccio K., Pitzurra L., Bellocchio S., Velardi A., Rasi G., Di Francesco P., and Garaci E. Thymosinα1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103 (2004) 4232-4239
13. Shiau A.L., Lin P.R., Chang M.Y., and Wu C.L. Retrovirus-mediated transfer of prothymosin gene inhibits tumor growth and prolongs survival in murine bladder cancer. Gene Ther. 8 (2001) 1609-1617
14. Voutsas I.F., Baxevanis C.N., Gritzapis A.D., Missitzis I., Stathopoulos G.P., Archodakis G., Banis C., Voelter W., and Papamichail M. Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas. Cancer Immunol. Immunother. 49 (2000) 449-458
15. Heidecke H., Eckert K., Schulze-Forster K., and Maurer H.R. Prothymosinα1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients. Int. J. Immunopharmacol. 19 (1997) 413-420
16. Garbin F., Eckert K., Immenschuh P., Kreuser E.D., and Maurer H.R. Prothymosinα1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients. Int. J. Immunopharmacol. 19 (1997) 323-332
17. Eckert K., Grunberg E., Immenschuh P., Garbin F., Kreuser E.D., and Maurer H.R. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosinα1. J. Cancer Res. Clin. Oncol. 123 (1997) 420-428
18. Baxevanis C.N., Gritzapis A.D., Spanakos G., Tsitsilonis O.E., and Papamichail M. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha. Cancer Immunol. Immunother. 40 (1995) 410-418
19. Orre R.S., Cotter II M.A., Subramanian C., and Robertson E.S. Prothymosin alpha functions as a cellular oncoprotein by inducing transformation of rodent fibroblasts in vitro. J. Biol. Chem. 276 (2001) 1794-1799
20. Ben-Yosef T., Yanuka O., Halle D., and Benvenisty N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 17 (1998) 165-171
21. Garnier M., Di Lorenzo D., Albertini A., and Maggi A. Identification of estrogen-responsive genes in neuroblastoma SK-ER3 cells. J. Neurosci. 17 (1997) 4591-4599
22. Wu C.G., Boers W., Reitsma P.R., van Deventer S.J., and Chamuleau R.A. Overexpression of prothymosin alpha, concomitant with c-myc, during rat hepatic carcinogenesis. Biochem. Biophys. Res. Commun. 232 (1997) 817-821
23. Lutz W., Stohr M., Schurmann J., Wenzel A., Lohr A., and Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13 (1996) 803-812
24. Moll J., Schmid P., Sansig G., and van der Putten H. The pattern of prothymosin alpha gene expression coincides with that of myc proto-oncogenes during mouse embryogenesis. Histochem. J. 28 (1996) 45-52
25. Mori M., Barnard G.F., Staniunas R.J., Jessup J.M., Steele Jr. G.D., and Chen L.B. Prothymosin-alpha mRNA expression correlates with that of c-myc in human colon cancer. Oncogene 8 (1993) 2821-2826
26. Wu C.L., Shiau A.L., and Lin C.S. Prothymosin alpha promotes cell proliferation in NIH3T3 cells. Life Sci. 61 (1997) 2091-2101
27. Tsitsilonis O.E., Bekris E., Voutsas I.F., Baxevanis C.N., Markopoulos C., Papadopoulou S.A., Kontzoglou K., Stoeva S., Gogas J., Voelter W., and Papamichail M. The prognostic value of alpha-thymosins in breast cancer. Anticancer Res. 18 (1998) 1501-1508
28. Sasaki H., Fujii Y., Masaoka A., Yamakawa Y., Fukai I., Kiriyama M., Saito Y., and Matsui H. Elevated plasma thymosin-α1 levels in lung cancer patients. Eur. J. Cardiothorac. Surg. 12 (1997) 885-891
29. Wu C.G., Habib N.A., Mitry R.R., Reitsma P.H., van Deventer S.J., and Chamuleau R.A. Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma. Br. J. Cancer 76 (1997) 1199-1204
30. Naruse H., Hashimoto T., Yamakawa Y., Iizuka M., Yamada T., and Masaoka A. Immunoreactive thymosinα1 in human thymus and thymoma. J. Thorac. Cardiovasc. Surg. 106 (1993) 1065-1071
31. Dominguez F., Magdalena C., Cancio E., Roson E., Paredes J., Loidi L., Zalvide J., Fraga M., Forteza J., Regueiro B.J., et al. Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur. J. Cancer 29A (1993) 893-897
32. Mitani M., Kuwabara Y., Kawamura H., Sato A., Hattori K., and Fujii Y. Significance of plasma thymosinα1 measurements in gastric cancer patients. World J. Surg. 24 (2000) 455-458
33. Bodey B., Bodey Jr. B., Siegel S.E., and Kaiser H.E. Review of thymic hormones in cancer diagnosis and treatment. Int. J. Immunopharmacol. 22 (2000) 261-273
34. Roy R., Singh S.M., Shanker A., and Sodhi A. Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin alpha-1. Int. J. Immunopharmacol. 22 (2000) 309-321
35. Li C.L., Zhang T., Saibara T., Nemoto Y., Ono M., Akisawa N., Iwasaki S., Maeda T., and Onishi S. Thymosinα1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. Int. Immunopharmacol. 2 (2002) 39-46
36. Shrivastava P., Singh S.M., and Singh N. Effect of thymosinα1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells. J. Biomed. Sci. 11 (2004) 623-630
37. Alldinger I., Dittert D., Peiper M., Fusco A., Chiappetta G., Staub E., Lohr M., Jesnowski R., Baretton G., Ockert D., Saeger H.D., Grutzmann R., and Pilarsky C. Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology 5 (2005) 370-379
38. Furukawa T., Duguid W.P., Rosenberg L., Viallet J., Galloway D.A., and Tsao M.S. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 148 (1996) 1763-1770
39. Ouyang H., Mou L., Luk C., Liu N., Karaskova J., Squire J., and Tsao M.S. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am. J. Pathol. 157 (2000) 1623-1631
40. Li M., Yang H., Chai H., Fisher W.E., Wang X., Brunicardi F.C., Yao Q., and Chen C. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 101 (2004) 2341-2350
41. Li M., Zhang R., Li F., Wang H., Kim H.J., Becnel L., Yao Q., Chen C., and Fisher W.E. Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue. J. Am. Coll. Surg. 201 (2005) 571-578
42. Loidi L., Vidal A., Zalvide J.B., Puente J.L., Reyes F., and Dominguez F. Development of ELISA to estimate thymosinα1, the N-terminus of prothymosin alpha, in human tumors. Clin. Chem. 43 (1997) 59-63
43. Sodhi A., and Paul S. Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosinα1. Int. Immunopharmacol. 2 (2002) 47-58
44. Urosevic M., and Dummer R. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin. Cancer Biol. 13 (2003) 337-342
45. Terabe M., Park J.M., and Berzofsky J.A. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol. Immunother. 53 (2004) 79-85
46. Witowski J., Ksiazek K., and Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol. Life Sci. 61 (2004) 567-579
47. Maggio E., van den Berg A., Diepstra A., Kluiver J., Visser L., and Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann. Oncol. 13 Suppl. 1 (2002) 52-56
48. Wrobel T., Mazur G., Jazwiec B., and Kuliczkowski K. Interleukin-17 in acute myeloid leukemia. J. Cell Mol. Med. 7 (2003) 472-474
49. Ciree A., Michel L., Camilleri-Broet S., Jean Louis F., Oster M., Flageul B., Senet P., Fossiez F., Fridman W.H., Bachelez H., and Tartour E. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int. J. Cancer 112 (2004) 113-120
50. Numasaki M., Fukushi J., Ono M., Narula S.K., Zavodny P.J., Kudo T., Robbins P.D., Tahara H., and Lotze M.T. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (2003) 2620-2627